Skip to main content
Download PDF

Co-deposition of SOD1, TDP-43 and p62 proteinopathies in ALS: evidence for multifaceted pathways underlying neurodegeneration

Acta Neuropathologica Communications volume 10, Article number: 122 (2022) Cite this article

Abstract

Multiple neurotoxic proteinopathies co-exist within vulnerable neuronal populations in all major neurodegenerative diseases. Interactions between these pathologies may modulate disease progression, suggesting they may constitute targets for disease-modifying treatments aiming to slow or halt neurodegeneration. Pairwise interactions between superoxide dismutase 1 (SOD1), TAR DNA-binding protein 43 (TDP-43) and ubiquitin-binding protein 62/sequestosome 1 (p62) proteinopathies have been reported in multiple transgenic cellular and animal models of amyotrophic lateral sclerosis (ALS), however corresponding examination of these relationships in patient tissues is lacking. Further, the coalescence of all three proteinopathies has not been studied in vitro or in vivo to date. These data are essential to guide therapeutic development and enhance the translation of relevant therapies into the clinic. Our group recently profiled SOD1 proteinopathy in post-mortem spinal cord tissues from familial and sporadic ALS cases, demonstrating an abundance of structurally-disordered (dis)SOD1 conformers which become mislocalized within these vulnerable neurons compared with those of aged controls. To explore any relationships between this, and other, ALS-linked proteinopathies, we profiled TDP-43 and p62 within spinal cord motor neurons of the same post-mortem tissue cohort using multiplexed immunofluorescence and immunohistochemistry. We identified distinct patterns of SOD1, TDP43 and p62 co-deposition and subcellular mislocalization between motor neurons of familial and sporadic ALS cases, which we primarily attribute to SOD1 gene status. Our data demonstrate co-deposition of p62 with mutant and wild-type disSOD1 and phosphorylated TDP-43 in familial and sporadic ALS spinal cord motor neurons, consistent with attempts by p62 to mitigate SOD1 and TDP-43 deposition. Wild-type SOD1 and TDP-43 co-deposition was also frequently observed in ALS cases lacking SOD1 mutations. Finally, alterations to the subcellular localization of the three proteins were tightly correlated, suggesting close relationships between the regulatory mechanisms governing the subcellular compartmentalization of these proteins. Our study is the first to profile spatial relationships between SOD1, TDP-43 and p62 pathologies in post-mortem spinal cord motor neurons of ALS patients, previously only studied in vitro. Our findings suggest interactions between these three key ALS-linked proteins are likely to modulate the formation of their respective proteinopathies, and perhaps the rate of motor neuron degeneration, in ALS patients.

Introduction

Intracellular mislocalization and deposition of key proteins is a neuropathological hallmark of all neurodegenerative diseases, and these processes are believed to contribute to neuron death within vulnerable regions of the brain and spinal cord in these disorders [42]. Research in this field has traditionally focussed on individual proteins known to form characteristic pathologies in each disorder, such as α-synuclein in Parkinson’s disease, β-amyloid or tau in Alzheimer’s, TAR DNA-binding protein 43 (TDP-43) or superoxide dismutase 1 (SOD1) in amyotrophic lateral sclerosis. Increasingly however, multiple types of proteinopathy have been demonstrated within vulnerable neurons in these disorders, sparking interest in potential synergies between these pathologies and their contribution to disease pathogenesis [43]. Biochemical mechanisms underlying the interaction and co-deposition of these proteins are currently poorly understood, with available data primarily derived from in vitro and in vivo models which are not able to accurately recapitulate complex aggregation proteomes observed in patient brains. Whilst these investigations provide important clues about potential mechanisms by which two proteins may interact, it is essential to conduct parallel investigations in patient tissues to confirm whether interactions identified in model systems actually occur in the human central nervous system. We are most likely to advance our understanding of the key drivers of neurodegeneration in these disorders by combining data from both avenues of investigation, including identifying promising therapeutic targets in the process.

Pairwise interactions between SOD1, TDP-43 and ubiquitin-binding protein 62/sequestosome 1 (p62) proteinopathies have been reported in multiple transgenic cellular and animal models of amyotrophic lateral sclerosis (ALS), however patient data is lacking. SOD1 is an important antioxidant protein, and was the first dominantly-inherited genetic risk factor for ALS [40]. Mutations to the SOD1 gene, together with atypical post-translational modification of SOD1 protein, promote misfolding, dysfunction and deposition of the protein, which are collectively strongly implicated in motor neuron degeneration in this disorder [48]. TDP-43 is an essential DNA/RNA binding protein that regulates transcription, alternative splicing and mRNA stability, and is predominantly localized within the nucleus in healthy neurons [12]. In ALS TDP-43 undergoes extensive atypical post-translational modification, resulting in its nucleocytoplasmic mislocalization, cytoplasmic accumulation and aggregation [44]. Pathological TDP-43 and SOD1 exhibit cross-seeding behaviours in cultured neurons [36, 50], however are rarely identified within the same spinal cord motor neurons in post-mortem tissues from ALS patients, questioning whether interactions identified in vitro are translatable to human ALS pathogenesis. Another ALS hallmark protein, p62, regulates autophagy and the shuttling of ubiquitinated proteins for degradation by the ubiquitin–proteasome system (UPS) in healthy neurons [24]. p62 is a reliable component of cytoplasmic protein inclusions in spinal cord motor neurons of sporadic (s)ALS cases [33]. p62 directly interacts with mutant, but not wild-type, SOD1 and is reported to enhance formation of non-toxic mutant SOD1 aggregates in cellular and murine models of SOD1-linked (SOD1-)fALS [17], however corresponding data from SOD1-fALS patients is lacking. p62 also mitigates TDP-43 aggregation in an autophagy- and proteasome-dependent manner in cultured neuronal progenitors [5], with co-deposition of these proteins reported in post-mortem spinal cord tissues from sALS patients. Importantly, the coalescence of SOD1, TDP-43 and p62 proteinopathies has not been assessed in vitro or in vivo to date, and may inform on novel therapeutic approaches capable of slowing or halting the development of multiple damaging co-pathologies.

Our group recently reported the accumulation and mislocalization of structurally-disordered (dis)SOD1 protein in spinal cord motor neurons of SOD1-fALS, non-SOD1-linked (non-SOD1-)fALS and sALS cases [47]. To examine relationships between this, and other, ALS-linked proteinopathies, we constructed overlapping spatial profiles of disSOD1, TDP-43 and p62 proteinopathies in post-mortem spinal cord tissues using a combination of DAB immunohistochemistry and multiplexed immunofluorescence microscopy. Our data reveal distinct SOD1, TDP-43 and p62 aggregation profiles within motor neurons of SOD1-fALS, non-SOD1-fALS and sALS cases. We demonstrate close spatial relationships between disordered SOD1, pathological TDP-43 and p62 pathologies within these neurons, suggesting interactions between these proteins modulate the formation of their respective proteinopathies.

Methods

Human post-mortem tissues

Post-mortem tissue cases utilized in this study are the same as those employed in our related study examining disSOD1 pathology and post-translational modification in ALS [47]. Formalin-fixed and fresh-frozen human post-mortem spinal cord tissues from patients with SOD1-associated familial amyotrophic lateral sclerosis (SOD1-fALS; n = 3), non-SOD1-associated fALS (non-SOD1-fALS; n = 4), sporadic ALS (sALS; n = 9) and age-matched controls (n = 10) were obtained from the MRC London Neurodegenerative Diseases Brain Bank (King’s College, London, UK) and the University of Maryland Brain and Tissue Bank, a biorepository of the NIH NeuroBioBank (Maryland, USA). Power analyses of data describing the proportion of motor neurons exhibiting granular SOD1, nuclear TDP-43 or p62 pathology in the ventral spinal cord of sALS cases (n = 7) compared with age-matched controls (n = 9) demonstrated that an n of 7 cases per diagnostic group was strongly powered to detect differences in pathological features of interest (100% power, two-tailed t-test, α = 5%; SPSS software, IBM, Armonk, NY, USA). Sample sizes were limited for SOD1-fALS (n = 3) and non-SOD1-fALS (n = 4) ALS subgroups due to the rarity of these tissues, however retrospective power analyses demonstrated our study was strongly powered to detect differences in these tissues compared with age-matched controls due to large effect sizes observed for these variables (99.9–100% power for data describing the proportion of motor neurons exhibiting granular SOD1, nuclear TDP-43 or p62 pathology). Clinical diagnoses of ALS were determined using patient histories received from the donors' physicians, and pathological identification of spinal cord motor neuron loss by brain bank neuropathologists confirmed clinical diagnoses. All ALS cases were free of other neurological or neuropathological conditions. Age-matched control cases were free of any clinically diagnosed neurological disorders and neuropathological abnormalities. Demographic and clinical information for all cases are detailed in Additional file 1: Table S1. We were unable to statistically evaluate whether sex influenced any measured variables due to small n’s. Neither age nor post-mortem interval were significantly correlated with any measured variables of interest in this study.

Formalin-fixed tissues were obtained from the cervical and thoracic spinal cord of all cases for immunohistochemical analyses, and fresh-frozen tissue obtained from the occipital cortex for SOD1 and C9ORF72 genotyping. Formalin-fixed tissues were embedded in paraffin and 7 µm sections prepared for immunohistochemical analyses. Post-mortem cases were randomly numbered by a secondary investigator prior to experimentation to blind primary investigators to case diagnoses.

SOD1 and C9ORF72 genotyping

SOD1 and C9ORF72 genotyping was performed in our post-mortem ALS and control cases as previously described [28]. DNA extraction from human brain tissue was performed using the DNeasy DNA extraction kit (Cat. #69506; Qiagen, Hilden, Germany), according to manufacturer’s instructions. All five exons of SOD1, together with greater than 10 bp of flanking sequence, were sequenced using PCR amplification and Sanger sequencing. The C9orf72 hexanucleotide repeat sequence was amplified using the repeat primed PCR method, and was subsequently analysed by fragment analysis [28]. Pathogenic status of the C9ORF72 gene was defined as greater than 30 repeats of the hexanucleotide GGGGCC expansion within the first intron of the C9ORF72 gene [37]. All results were independently analysed by two team members. Inconclusive samples were repeated until a conclusive result was obtained. Positive samples were repeated twice to confirm results. Mutations in the SOD1 gene were identified in ALS cases 11 (I113T), 12 (I113T) and 13 (D101G), whereas hexanucleotide repeat expansions in the C9ORF72 gene were identified in ALS cases 14, 16 and 17 (Additional file 1: Table S1).

Immunohistochemistry

Seven-micron fixed tissue sections used for 3,3′-Diaminobenzidine (DAB) staining and brightfield microscopy were deparaffinated using xylene and graded ethanol. Antigen retrieval was performed in citrate buffer (pH 6; Fronine, Australia) at 95 °C for 30 min. Sections were washed with 50% ethanol, incubated with 3% H2O2 (Fronine, Australia) in 50% ethanol to quench non-specific peroxidase activity, and blocked in 0.5% casein, 1% bovine serum albumin diluted in PBS for 1.5 h at room temperature. Sections were incubated overnight with appropriate primary antibodies diluted in blocking solution (Additional file 1: Table S3), and primary antibodies detected using biotinylated IgG secondary antibodies (2 h, room temperature, 1:200 diluted in blocking solution) (Vector Laboratories, Burlingame, CA) followed by Vector Elite Kit tertiary antibody complex (2 h, room temperature, 1:100 diluted in PBS) (Vector Laboratories, Burlingame, CA). Antibody binding was visualised using a DAB (Sigma) solution containing cobalt and nickel ions, changing the chromogen colour from brown to black. Sections were finally dehydrated using graded ethanol and xylene, and mounted with DPX. Staining was visualized and imaged using an Olympus VS 120 Slide Scanner at 40 × magnification (Olympus-life science, Shinjuku, Tokyo, Japan), and images processed using OlyVIA (Version 3.1; Olympus-life science) or Fiji (National Institute of Health (NIH)) software. A no primary negative control was also included for each diagnostic group to identify protocol- and tissue-related artefacts independent of primary antibody immunoreactivity (Additional file 1: Figure S1), involving tissues processed as above but in the absence of primary antibodies.

Quantification of DAB-immunostained pathological features of interest

Immunostaining for p62 and TDP-43 was performed in ventral horn grey matter of the cervical and thoracic spinal cord as above, using appropriate primary antibodies (Additional file 1: Table S3). TDP-43 immunostaining utilized antibodies recognizing a phosphorylated C-terminal fragment of TDP-43, commonly implicated in TDP-43 deposition (pathological TDP-43; pTDP-43), as well as non-phosphorylated TDP-43. Pathologies of interest were intracellular pTDP-43 deposits, diffuse cytosolic pTDP-43, nuclear TDP-43, intracellular p62 deposits, diffuse cytosolic p62, and nuclear p62. Motor neurons were considered to be negative for a given pathology of interest if they exhibited no immunoreactivity for that pathology, e.g. if no nuclear TDP-43 immunoreactivity was present then that motor neuron was counted as nuclear TDP-43 negative. Counts of each pathology were expressed as the proportion of neurons exhibiting evidence of that pathology to account for differences in motor neuron number between cervical and thoracic spinal cord levels. The number of cells counted to quantify each pathology of interest are presented in (Additional file 1: Table S4).

Multiplexed immunofluorescence

Fluorescent staining and confocal microscopy employed 7 µm fixed tissue sections, which were deparaffinated, antigen retrieved, quenched, blocked and incubated with appropriate primary antibodies (Additional file 1: Table S3) as above. Multiplexed fluorescent immunolabelling was performed using OPAL fluorophores and spectral DAPI (Akoya Biosciences, Menlo Park, CA, USA) according to the manufacturer’s instructions. Antibodies were stripped in between OPAL fluorophore incubations by incubating sections in AR6 commercial buffer (Akoya Biosciences, USA) at 95 °C for 40 min. After fluorophore incubations sections were washed with PBS and cover-slipped with 80% glycerol. Images were collected at 60 × magnification using a Nikon C2 + Confocal Microscope System (Nikon, Minato City, Tokyo, Japan) and Nikon NIS-elements software (Version 5.20.02; Nikon, Japan), and were viewed and analysed using Fiji software (National Institute of Health, Bethesda, Maryland, USA).

As above, a no primary negative control was included for each diagnostic group to identify non-specific fluorescent signals originating from autofluorescent tissue features (e.g. lipofuscin) or direct binding of secondary antibodies to tissues (Additional file 1: Figure S1). During acquisition of double- or triple-immunolabelled fluorescent images a sequential protocol was used where each fluorophore was excited and the corresponding channel individually acquired, before moving onto the next fluorophore and channel. This minimized spectral cross-contamination between OPAL650, OPAL620 and OPAL520 fluorophores (Additional file 1: Figure S1).

Quantification of SOD1, TDP-43 and p62 pathology colocalization

Ten spinal cord tissue sections from each diagnostic group, including at least one section from all available cases, were immunostained for disordered SOD1, pTDP-43 and p62, and cell nuclei counterstained with DAPI. We then imaged all motor neurons within these sections exhibiting evidence of disordered SOD1, pTDP-43 or p62 neuropathological abnormalities. We imaged a total of 84, 104 and 123 motor neurons in SOD1-fALS, non-SOD1-fALS and sALS cases, respectively (Additional file 1: Table S4). Where multiple pathologies were present within an imaged motor neuron, we also noted whether there was spatial overlap (colocalization) or whether the pathologies were coincidental within an individual neuron. To reconcile differences in the total number of motor neurons imaged for each group, quantitative data on colocalization or coincidence of the three pathologies was expressed as the proportion of imaged motor neurons exhibiting evidence of that condition.

Statistical analyses

Statistical analyses were performed using PASW v18 (SPSS inc., Chicago, IL, USA). Parametric tests or descriptive statistics with parametric assumptions (one-way ANOVA, Pearson's r) were used for variables (proportions of motor neurons with pTDP-43 pathology or nuclear TDP-43) meeting the associated assumptions. Non-parametric tests or statistics (Kruskal–Wallis H test, Spearman's r) were used for variables (proportions of motor neurons with p62 pathology or nuclear p62) where the observed data did not fit the assumptions of parametric tests. Data normality was assessed using the D'Agostino-Pearson and Shapiro–Wilk normality tests, whereby both tests needed to be passed for data to meet the assumption of a normal distribution. Outliers were identified using the combined robust regression and outlier removal (ROUT) method with a maximum false discovery rate of 5%. Final values were reported as mean ± SEM. A p value of less than 0.05 was accepted as the level of significance.

Results

Nucleocytoplasmic TDP-43 mislocalization and aggregation are associated with disSOD1 pathology in post-mortem ALS ventral spinal cord

Phosphorylation and C-terminal fragmentation of TDP-43 are central to its pathological aggregation in vitro and in vivo [4, 21], and phosphorylated TDP-43 is heavily enriched in TDP-43 aggregates in post-mortem spinal cord tissues from ALS cases [21]. Using a monoclonal TDP-43 antibody specifically recognizing phosphorylated, C-terminal TDP-43 (pTDP-43), we identified diffuse cytoplasmic pTDP-43 immunoreactivity within spinal cord motor neurons of all ALS cases, but only three-of-nine controls (Fig. 1a, Table 1). Cytoplasmic pTDP-43-immunopositive motor neuron inclusions of varying morphologies were also present within three-of-four non-SOD1-fALS cases, all seven sALS cases, and three-of-nine control cases, but were absent within SOD1-fALS cases (Fig. 1a, Table 1). The proportion of motor neurons exhibiting either form of pTDP-43 pathology was negligible in control cases (0.4%) compared with all ALS subgroups (24–58%; Fig. 1b, Table 1).

Fig. 1
figure 1

TDP-43 cytoplasmic mislocalization and deposition in the vulnerable ventral spinal cord of ALS cases. a Both pan and phosphorylated (p)TDP-43 antibodies identified diffuse cytoplasmic TDP-43 staining (arrows), as well as punctate (dotted arrowheads), globular (single downwards arrowheads) and fibrillar skein-like (double downwards arrowheads) TDP-43-immunopositive inclusions, in ventral spinal cord motor neurons of all ALS cases and a small proportion of controls. Pan TDP-43 immunostaining also revealed nuclear TDP-43 (open arrowheads) in ventral spinal cord motor neurons of ALS cases and controls. Case numbers (Additional file 1: Table S1) are listed in the top left corner of each panel. b, c The proportion of motor neurons possessing diffuse cytoplasmic TDP-43 or cytoplasmic TDP-43 inclusions (collectively termed TDP-43 pathology) was higher in ALS cases compared with controls (b; One-way ANOVA with Holm-Sidak’s multiple comparisons post-hoc tests; SOD1-fALS: p = 0.05; non-SOD1-fALS: p < 0.0001; sALS: p < 0.0001), whereas the proportion of motor neurons exhibiting nuclear TDP-43 immunostaining was significantly reduced in ALS cases compared with controls (c; One-way ANOVA with Holm-Sidak’s multiple comparisons post-hoc tests, p < 0.0001 for all comparisons). Data in b and c represent mean ± SEM. *p < 0.05, ****p < 0.0001. d Phosphorylated (p)TDP-43 pathology is absent within control, SOD1-fALS and sALS spinal cord motor neurons exhibiting non-pathological nuclear TDP-43 (open arrowheads) and granular SOD1 immunostaining (closed arrowheads). Scale bars in a and d represent 25 µm. Antibody details are listed in Additional file 1: Table S3. No immunostaining was observed in spinal cord tissue sections processed as above in the absence of primary antibodies (Additional file 1: Figure S1)

Full size image
Table 1 Characterization and quantification of pTDP-43-immunopositive spinal cord motor neuron (MN) inclusions, as well as diffuse cytoplasmic pTDP-43 staining and nuclear pan TDP-43 immunoreactivity, in seven micron paraffin-embedded formalin-fixed tissue sections of the cervical and thoracic spinal cord from all post-mortem tissue cases
Full size table

The development of cytoplasmic TDP-43 pathology is thought to be driven by nucleocytoplasmic TDP-43 mislocalization in cellular and animal models of ALS [44]. We utilized a polyclonal pan TDP-43 antibody to assess the subcellular localization of full-length TDP-43 in ALS and control spinal cord motor neurons, revealing a 6.5-fold reduction in the proportion of motor neurons possessing nuclear TDP-43 in all ALS subgroups compared with controls (range: 3.7-to-9.5-fold; Fig. 1a, c, Table 1). A reduction in the proportion of motor neurons possessing nuclear TDP-43 was strongly correlated with a higher proportion of motor neurons exhibiting cytoplasmic pTDP-43 pathology (Fig. 2), reinforcing existing data demonstrating a close interdependence between TDP-43 phosphorylation, mislocalization and aggregation in spinal cord motor neurons in ALS [34]. A greater proportion of motor neurons exhibiting nuclear TDP-43 export and cytoplasmic pTDP-43 pathology was also correlated with more severe motor neuron degeneration (Fig. 2), supporting a role for these changes in ALS pathogenesis.

Fig. 2
figure 2

Neuropathological correlates of SOD1, TDP43 and p62 proteinopathies in spinal cord motor neurons of post-mortem ALS and control cases. Quantitative data describing disordered SOD1 (DisSOD1) pathology, neuronal loss and the proportion of motor neurons exhibiting DisSOD1 mislocalization in the spinal cord of our post-mortem tissue cohort are published in a related article [47]. Spearman’s r coefficient (top) and the p value (bottom) of each correlation are stated within panel. Positive and negative Spearman’s r coefficients are delineated by a binary colour gradient. n = 33–35 data points for each correlation. A correlation is considered to be strong if Spearman’s r = 0.5 or higher. Asterisks indicate statistically significant correlations

Full size image

Strong positive correlations were identifed between the proportion of motor neurons exhibiting cytoplasmic pTDP-43 pathology or nuclear TDP-43 depletion, and disSOD1 mislocalization (Fig. 2) [47], suggesting regulatory pathways governing the subcellular compartmentalization of these two proteins are either shared or closely related. Co-localization immunofluorescence reinforced this relationship, confirming the absence of cytoplasmic disSOD1 or pTDP-43 pathology within motor neurons exhibiting non-pathological nuclear TDP-43 and granular SOD1 immunostaining (Fig. 1d). On the contrary, a correlation was also observed between the proportion of motor neurons exhibiting cytoplasmic disSOD1 and pTDP-43 pathology (Fig. 2), suggesting common factors driving the deposition of these proteins.

Cytoplasmic p62 accumulation and deposition is associated with ALS-linked pathologies in the degenerating ALS spinal cord

p62-immunoreactive motor neuron inclusions are a reliable hallmark of sALS in post-mortem patient spinal cord tissues [33], however the presence of this pathology in SOD1- and non-SOD1-fALS cases is less well understood. Immunostaining of post-mortem spinal cord tissues for p62 revealed inclusions of varying morphologies within 42–56% of motor neurons in all ALS cases, but only 4% of motor neurons in one-of-seven controls (Fig. 3a, Table 2). In addition to inclusions, strong diffuse cytoplasmic p62 immunostaining was observed within 36–63% of motor neurons in one-of-three SOD1-fALS cases, all four non-SOD1-fALS cases and five-of-seven sALS cases, but only 4% of motor neurons in three-of-nine control cases (Fig. 3a, Table 2). Collectively, these data demonstrate that cytoplasmic p62 accumulation and deposition are a common (72–76%) feature of all types of ALS, but are rarely present in healthy controls (2%; Fig. 3a, b, Table 2). These data are consistent with the accepted physiological function of this protein in sequestering toxic misfolded proteins into non-toxic cytoplasmic protein aggregates for clearance by autophagy or the UPS [17]; it is likely that such aggregates accumulate over time as disease severity increases and downstream proteostatic pathways become increasingly dysfunctional. Higher proportions of motor neurons exhibiting nuclear p62 depletion or cytoplasmic p62 pathology were indeed correlated with higher proportions of motor neurons possessing disSOD1 or pTDP-43 pathologies (Fig. 2).

Fig. 3
figure 3

Altered p62 localization and deposition in the vulnerable ventral spinal cord of ALS cases. a p62 immunostaining revealed nuclear p62 (open arrowheads) in ventral spinal cord motor neurons of one ALS case and all controls. Diffuse cytoplasmic p62 staining (arrows), as well as punctate (dotted arrowheads), globular (single downwards arrowheads) and fibrillar skein-like (double downwards arrowheads) p62-immunopositive inclusions, were also identified in ventral spinal cord motor neurons of all ALS cases and a small proportion of controls. Case numbers (Additional file 1: Table S1) are listed in the top left corner of each panel and scale bars represent 25 µm. Antibody details are listed in Supplementary Table 3. No immunostaining was observed in spinal cord tissue sections processed as above in the absence of primary antibodies (Additional file 1: Figure S1). b The proportion of motor neurons exhibiting diffuse cytoplasmic p62 or cytoplasmic p62 inclusions (collectively termed atypical p62) was higher in ALS cases compared with controls (Kruskal–Wallis H test with Dunn’s multiple comparisons post-hoc tests; SOD1-fALS: p = 0.018; non-SOD1-fALS: p = 0.0006; sALS: p = 0.0002). c In contrast, nuclear p62 immunostaining was absent in all but one ALS case (open red circle), resulting in a significant reduction in the proportion of motor neurons exhibiting nuclear p62 compared with controls (Kruskal–Wallis H test with Dunn’s multiple comparisons post-hoc tests; SOD1-fALS: p = 0.01; non-SOD1-fALS: p = 0.004; sALS: p < 0.0001). Data in b and c represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

Full size image
Table 2 Characterization and quantification of p62-immunopositive spinal cord motor neuron (MN) inclusions, as well as diffuse cytoplasmic and nuclear p62 staining, in seven micron paraffin-embedded formalin-fixed tissue sections of the cervical and thoracic spinal cord from all post-mortem tissue cases
Full size table

Mechanistically, the accumulation and deposition of p62 in the cytoplasm is associated with a down-regulation of nucleocytoplasmic p62 shuttling in cultured non-neuronal cells [35]. This mechanism is also likely to be present in patients as nuclear p62 immunoreactivity was absent in spinal cord motor neurons of all but one ALS case, but was observed within up to 24% of control motor neurons (Fig. 3a, c; Table 2). As further evidence to this effect, the proportion of motor neurons exhibiting nuclear p62 and cytoplasmic p62 pathology were strongly inversely correlated (Fig. 2).

A spectrum of overlapping disSOD1, pTDP-43 and p62 pathologies exist in post-mortem ALS spinal cord motor neurons

Given the apparent relationships between the presence of disSOD1 [47], TDP-43 and p62 pathologies in motor neurons in post-mortem ALS spinal cord tissues, we then employed multiplexed immunofluorescence microscopy to evaluate potential spatial interactions between these pathologies. Between 84 and 123 individual motor neurons exhibiting evidence of cytoplasmic disordered SOD1, pTDP-43 or p62 pathology were imaged in each of the three ALS subgroups, noting the presence of spatial overlap (colocalization) or segregation (coincidence) between pathologies where multiple were present within an imaged motor neuron.

Disordered SOD1 pathology was present within a significant proportion of SOD1-fALS (75%), non-SOD1-fALS (42%) and sALS (47%) spinal cord motor neurons examined. Although pathological TDP-43 and mutant SOD1 exhibit a strong bilateral cross-seeding relationship in vitro [23, 36, 50], pathological TDP-43 was rarely (4%) present within spinal cord motor neurons of SOD1-fALS cases exhibiting disordered mutant SOD1 pathology (Fig. 4), in agreement with previous studies [25]. In contrast to SOD1-fALS cases, pTDP-43 pathology was present within 38–64% of neurons exhibiting wild-type disSOD1 pathology in non-SOD1-fALS and sALS cases, and 29–35% of pTDP-43-containing neurons possessed wild-type disSOD1 pathology (Fig. 5). Considering disordered wild-type SOD1 and pTDP-43 pathologies were primarily coincidental within these motor neurons (Fig. 5b), it is unlikely that they exhibit direct cross-seeding behaviour, suggesting alternative common mediators promote the development of both pathologies in these sub-groups.

Fig. 4
figure 4

Coincidence and colocalization of disSOD1, pTDP-43 and p62 pathologies in spinal cord motor neurons of SOD1-fALS cases. a Immunostaining for disordered SOD1 (disSOD1), phosphorylated TDP-43 (pTDP-43) and p62 proteins using fluorescence microscopy in ventral spinal cord motor neurons of SOD1-fALS cases. We identified diffuse cytoplasmic staining (arrows), as well as punctate (dotted arrowheads), globular (single downwards arrowheads) and fibrillar skein-like (double downwards arrowheads) inclusions, comprised of one or more proteins of interest in these neurons. Rows represent each of the different combinations of pathologies observed in motor neurons of that subgroup; disSOD1 (magenta), pTDP-43 (blue) or p62 (cyan) deposition alone, disSOD1 and pTDP-43 (light pink), disSOD1 and p62 (orange), or pTDP-43 and p62 (light blue) co-deposition, or the co-deposition of all three pathologies (white). Scale bars in represent 25 µm. Antibody details are listed in Additional file 1: Table S3. No immunostaining was observed in spinal cord tissue sections processed as above in the absence of primary antibodies (Additional file 1: Figure S1). b A venn diagram illustrating the proportion of the 84 total motor neurons examined which exhibit each of the different individual or combined pathologies. Each segment corresponds to a row in panel a, and are pictured next to their corresponding row. Where co-deposition of two pathologies was observed within a motor neuron, we noted the presence (colocalized, grey) or absence (coincidental, black) of spatial overlap

Full size image
Fig. 5
figure 5

Coincidence and colocalization of disSOD1, pTDP-43 and p62 pathologies in spinal cord motor neurons of non-SOD1-fALS and sALS cases. a Immunostaining for disordered SOD1 (disSOD1), phosphorylated TDP-43 (pTDP-43) and p62 proteins using fluorescence microscopy in ventral spinal cord motor neurons of non-SOD1-fALS and sALS cases. We identified diffuse cytoplasmic staining (arrows), as well as punctate (dotted arrowheads), globular (single downwards arrowheads) and fibrillar skein-like (double downwards arrowheads) inclusions, comprised of one or more proteins of interest in these neurons. Rows represent each of the different combinations of pathologies observed in motor neurons of that subgroup; disSOD1 (magenta), pTDP-43 (blue) or p62 (cyan) deposition alone, disSOD1 and pTDP-43 (light pink), disSOD1 and p62 (orange), or pTDP-43 and p62 (light blue) co-deposition, or the co-deposition of all three pathologies (white). Scale bars in represent 25 µm. Antibody details are listed in Additional file 1: Table S3. No immunostaining was observed in spinal cord tissue sections processed as above in the absence of primary antibodies (Additional file 1: Figure S1). b A venn diagram illustrating the proportion of the total motor neurons examined (non-SOD1-fALS, n = 104; sALS, n = 123) which exhibit each of the different individual or combined pathologies. Each segment corresponds to a row in panel a, and are pictured next to their corresponding row. Where co-deposition of two pathologies was observed within a motor neuron, we noted the presence (colocalized, grey) or absence (coincidental, black) of spatial overlap

Full size image

Consistent with a role for p62 in binding mutant SOD1 and targeting it for clearance [17, 18], p62 was present within 79% of SOD1-fALS motor neurons exhibiting disordered mutant SOD1 pathology, and was colocalized with disordered mutant SOD1 pathology in 78% of these neurons (Fig. 4). No overlap was observed between p62 and pTDP-43 pathologies in SOD1-fALS cases, and therefore motor neurons exhibiting p62 pathology in the absence of mutant disSOD1 (24% of total surveyed population) may reflect efforts by p62 to promote the clearance of additional ALS-linked proteinopathies not examined in this study, including FUS [27]. In contrast to SOD1-fALS cases, p62 was only present within 13–17% of spinal cord motor neurons exhibiting disordered wild-type SOD1 pathology in non-SOD1-fALS and sALS cases (Fig. 5), reinforcing existing data demonstrating higher selectivity of p62 for mutant forms of the protein [17, 18]. Colocalization, rather than coincidence, of the two pathologies within the vast majority (75–100%) of this sub-population of non-SOD1-fALS and sALS motor neurons does, however, suggest a direct protein–protein interaction between p62 and wild-type SOD1.

As well as promoting the clearance of mutant SOD1 protein, p62 directly interacts with TDP-43 [46] and is reported to mitigate TDP-43 aggregation in an autophagy- and proteasome-dependent manner [5]. Despite its rarity in SOD1-fALS, pTDP-43 deposition was identified within a substantial proportion of non-SOD1-fALS (54%) and sALS (74%) spinal cord motor neurons examined in this study (Fig. 5). Consistent with previous studies conducted in post-mortem spinal cord tissues from sALS patients [11], 48–52% of pTDP-43-containing neurons exhibited p62 co-deposition in non-SOD1-fALS and sALS cases. These two pathologies were almost always (93.5–100%) colocalized, confirming a likely role for p62 in pathological TDP-43 clearance in vivo.

Discussion

This study constitutes the first examination of SOD1, TDP-43 and p62 co-deposition in post-mortem ventral spinal cord tissues from SOD1-fALS, non-SOD1-fALS and sALS patients. We identified changes in the abundance of each pathology individually, as well as in the spatial overlap and coincidence of the three pathologies, within vulnerable spinal cord motor neurons between our three ALS subgroups. Aligning with existing data [14, 15, 25], our findings reveal disparate SOD1, TDP-43 and p62 aggregation profiles between the three ALS subgroups. Whilst our data largely support findings obtained from cellular and animal models of ALS, we identified apparent discrepancies in relationships between the three pathologies observed in ALS cases, compared with those reported in models of this disorder. While disease models constitute invaluable tools for interrogating relationships between disease pathologies, our study highlights the importance of contextualizing conclusions obtained from these models using corresponding data obtained from post-mortem patient tissues.

All ALS-associated SOD1 mutations enhance the protein’s aggregation propensity [48], thus it is unsurprising that disordered mutant SOD1 protein constituted the dominant proteinopathy within motor neurons of SOD1-fALS cases in this study (Fig. 4). Significant mislocalization of disordered mutant SOD1 from the ER-golgi network to the cytoplasm accompanied SOD1 deposition within these neurons (related manuscript [47]), which we speculate may arise following inhibition of ER-golgi trafficking by mutant SOD1 itself [2]. Considering that disruption of protein transport along the ER-golgi axis constitutes an early event in SOD1-fALS pathogenesis [30], preceding protein aggregation [2], we propose that soluble nascent mutant SOD1, not aggregated mutant SOD1, may disrupt ER-golgi trafficking to promote cytoplasmic mutant SOD1 accumulation and deposition in motor neurons of SOD1-fALS cases. In addition to inhibiting ER-golgi transport, mutant SOD1 pathology is known to induce TDP-43 deposition in NSC-34 cells [50], and TDP-43 phosphorylation and C-terminal fragmentation in transgenic mice [23]. We, and others [25], however, found the presence of pTDP-43 pathology within motor neurons of SOD1-fALS cases to be extremely rare compared with abundant pTDP-43 pathology in motor neurons of other ALS subgroups (Figs. 4, 5). In addition to corroborating reports of a degree of phenotypic incongruence between common cellular and animal models of SOD1-fALS and human disease patients [39], our findings highlight the importance of recognizing that two proteins which possess the ability to interact in vitro may not necessarily participate in the same interaction in ALS patients. It must be acknowledged, however, that our data examines aggregated forms of both proteins, and does not inform on the likelihood of an interaction between soluble forms of these proteins in patients in vivo. In contrast to TDP-43 deposition, our data support a role for mutant SOD1 in inducing nucleocytoplasmic TDP-43 mislocalization (Figs. 1, 2), previously reported in NSC-34 cells [50]. The presence of TDP-43 mislocalization in the absence of overt cytoplasmic pTDP-43 pathology is strongly associated with neuronal toxicity in vitro [44], suggesting restoration of nuclear TDP-43, perhaps in combination with anti-aggregation therapies targeting disordered SOD1, may provide therapeutic benefit to SOD1-fALS patients.

Although substantial differences in aggregation profiles of SOD1, TDP-43 and p62 in SOD1-fALS, non-SOD1-fALS and sALS cases imply distinct pathways drive neurodegeneration in each ALS subgroup [11], the presence of common pathologies across subgroups indicates some pathways may be common to all patients, irrespective of the presence or absence of key gene mutations. Disordered SOD1 mislocalization and deposition are primarily attributed to SOD1 gene mutations, and yet their presence in almost half of all spinal cord motor neurons in non-SOD1-fALS and sALS cases highlights the presence of alternative factors which promote SOD1 pathology in these cases [47, 48]. Altered post-translational modification of wild-type SOD1 can result in structural disorder, catalytic dysfunction and deposition of the protein in vitro and in vivo [16, 48], conferring biochemical properties that mirror the most unstable of mutant proteins [19]. Consequently, we speculate that disordered wild-type SOD1 can induce ER-golgi dysfunction in NSC-34 cells through a similar mechanism to mutant SOD1 [45], which may contribute to the cytoplasmic accumulation of disordered wild-type SOD1 pathology in these cells [29]. We propose that these data suggest that, like mutant SOD1 in SOD1-fALS motor neurons, disordered wild-type SOD1 may promote its own mislocalization and deposition in motor neurons of non-SOD1-fALS and sALS patients. Independent of alterations to SOD1 per se, C9ORF72 hexanucleotide expansions are associated with elevated ER stress in induced pluripotent stem cells derived from C9ORF72-linked fALS patients [10] and pTDP-43 similarly inhibits ER-golgi transport in cultured Neuro2a cells [41]. We speculate that these data imply potential indirect contributions of these factors to wild-type SOD1 pathology in spinal cord motor neurons of non-SOD1-fALS and sALS cases in this study. Indeed, transfection-mediated overexpression of mutant and wildtype TDP-43 induces the accumulation of misfolded human wild-type SOD1 in cultured cell lines, as well as in primary spinal cord cells derived from human wild-type SOD1 transgenic mice [36]. Although such an association could be attributed to a direct cross-seeding interaction between these proteins in cases with SOD1 mutations, wild-type SOD1 and TDP-43 do not interact in cultured motor neuron-like cells [23], and negligible spatial overlap was observed between SOD1 and TDP-43 pathologies within non-SOD1-fALS and sALS motor neurons in this study (Fig. 5). Collectively, we propose that these data suggest pathological TDP-43 may promote disordered wild-type SOD1 pathology through an indirect mechanism, such as impaired ER-golgi trafficking. Irrelevant of the underlying cause, we speculate that impaired ER-golgi trafficking may promote cytoplasmic disordered wild-type SOD1 accumulation in motor neurons of non-SOD1-fALS and sALS patients [29], constituting a common pathway leading to neurotoxic cytoplasmic SOD1 pathology in all ALS subgroups examined in this study.

Whilst wild-type and mutant TDP-43 induce wild-type SOD1 pathology in vitro [36], there have been no investigations into whether disordered wild-type SOD1 reciprocally induces TDP-43 mislocalization or deposition. Given mutant SOD1 induces TDP-43 pathology [23, 50], and disordered wild-type SOD1 adopts similar conformations to mutant SOD1 [19], it is certainly plausible that disordered wild-type SOD1 may also induce TDP-43 pathology. Indeed, wild-type SOD1 pathology impairs ER-golgi trafficking [41, 45], UPS function [13], and autophagy [1, 22] through similar mechanisms to mutant SOD1, which may reduce the clearance of pathological TDP-43 to result in its cytoplasmic accumulation. Further investigations are warranted to dissect the complex relationship between these pathologies, which may identify common and tractable therapeutic targets capable of mitigating the progression of both pathologies simultaneously.

Current therapies targeting disordered SOD1 and pathological TDP-43 in ALS patients primarily aim to reduce expression levels [31], stabilize protein structure [3, 38, 49], correct protein mislocalization [6] or enhance clearance mechanisms [9]. Included in the latter of these approaches are a number of pharmacological inducers of autophagy, many of which have already completed (tamoxifen [8], ClinicalTrials.gov NCT02166944), are currently ongoing (ibudilast [9], ClinicalTrials.gov NCT04057898; rapamycin [26], ClinicalTrials.gov NCT03359538) or are scheduled to enter (trehalose [7]) clinical trials for ALS. Our findings support the development of such interventions by demonstrating an interaction between mutant SOD1 and p62 within motor neurons of SOD1-fALS cases (Fig. 4), previously only identified in vitro, and between wild-type SOD1, TDP-43 and p62 in non-SOD1-fALS and sALS motor neurons (Fig. 5). To our knowledge, we are the first to report this interaction between wild-type SOD1 and p62. SOD1 mutations exacerbate underlying structural flexibility within disordered SOD1 protein, providing a larger solvent-accessible surface area available for protein–protein interactions or post-translational modifications such as ubiquitin [48]. We speculate this may underlie the increased interaction between p62 and mutant SOD1, compared with wild-type SOD1, in our ALS cases; namely 4- and 8-fold increases in the spatial overlap between disordered SOD1 and p62 pathologies in motor neurons of SOD1-fALS cases compared with non-SOD1-fALS and sALS cases, respectively. Whilst our data support the development of therapies which enhance p62-mediated autophagy of disSOD1 and pathological TDP-43 in all forms of ALS, it must be acknowledged that this relies on the functionality of downstream protein quality control machinery; the proteasome and autophagosome, which become increasingly overwhelmed as ALS progresses [30]. Further, both knockout [20] and overexpression [32] of p62 accelerates motor neuron degeneration and the accumulation of ubiquitin-positive aggregates in spinal cord motor neurons of the same transgenic mutant SOD1 mouse strain, highlighting the need to regulate p62 levels and function within a tight range to achieve therapeutic benefit.

This study is the first to identify multiple relationships between disordered SOD1, pTDP-43 and p62 pathologies in spinal cord motor neurons of SOD1-fALS, non-SOD1-fALS and sALS cases, previously only studied in vitro. Comprehensive characterization of the relationships between these pathologies in all forms of ALS may advance our understanding of the multifaceted molecular pathways driving motor neuron death in this disorder, and identify potential therapeutic targets whose manipulation may slow or halt the development of damaging co-pathologies. We propose that investigation of novel therapies should optimally utilize cellular or animal model systems which more accurately express the range of ALS-linked co-pathologies identified in this study.

Availability of data and materials

The data and materials that support the findings of this study are available from the corresponding authors upon reasonable request.

Abbreviations

ALS:

Amyotrophic lateral sclerosis

C9ORF72:

Chromosome 9 open reading frame 72

disSOD1:

Structurally-disordered SOD1

ER:

Endoplasmic reticulum

fALS:

Familial amyotrophic lateral sclerosis

p62:

Ubiquitin-binding protein 62/sequestosome 1

sALS:

Sporadic amyotrophic lateral sclerosis

SOD1:

Superoxide dismutase-1

TDP-43:

TAR DNA-binding protein 43

References

  1. Amin A, Perera ND, Beart PM, Turner BJ, Shabanpoor F (2020) Amyotrophic lateral sclerosis and autophagy: dysfunction and therapeutic targeting. Cells. https://doi.org/10.3390/cells9112413

    Article  PubMed  PubMed Central  Google Scholar 

  2. Atkin JD, Farg MA, Soo KY, Walker AK, Halloran M, Turner BJ, Nagley P, Horne MK (2014) Mutant SOD1 inhibits ER-Golgi transport in amyotrophic lateral sclerosis. J Neurochem 129:190–204. https://doi.org/10.1111/jnc.12493

    Article  CAS  PubMed  Google Scholar 

  3. Benatar M, Wuu J, Andersen PM, Atassi N, David W, Cudkowicz M, Schoenfeld D (2018) Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology 90:e565–e574. https://doi.org/10.1212/WNL.0000000000004960

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Berning BA, Walker AK (2019) The pathobiology of TDP-43 C-terminal fragments in ALS and FTLD. Front Neurosci 13:335. https://doi.org/10.3389/fnins.2019.00335

    Article  PubMed  PubMed Central  Google Scholar 

  5. Brady OA, Meng P, Zheng Y, Mao Y, Hu F (2011) Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1. J Neurochem 116:248–259. https://doi.org/10.1111/j.1471-4159.2010.07098.x

    Article  CAS  PubMed  Google Scholar 

  6. Buratti E (2021) Targeting TDP-43 proteinopathy with drugs and drug-like small molecules. Br J Pharmacol 178:1298–1315. https://doi.org/10.1111/bph.15148

    Article  CAS  PubMed  Google Scholar 

  7. Castillo K, Nassif M, Valenzuela V, Rojas F, Matus S, Mercado G, Court FA, van Zundert B, Hetz C (2013) Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons. Autophagy 9:1308–1320. https://doi.org/10.4161/auto.25188

    Article  CAS  PubMed  Google Scholar 

  8. Chen PC, Hsieh YC, Huang CC, Hu CJ (2020) Tamoxifen for amyotrophic lateral sclerosis: a randomized double-blind clinical trial. Medicine (Baltimore) 99:e20423. https://doi.org/10.1097/MD.0000000000020423

    Article  CAS  Google Scholar 

  9. Chen Y, Wang H, Ying Z, Gao Q (2020) Ibudilast enhances the clearance of SOD1 and TDP-43 aggregates through TFEB-mediated autophagy and lysosomal biogenesis: the new molecular mechanism of ibudilast and its implication for neuroprotective therapy. Biochem Biophys Res Commun 526:231–238. https://doi.org/10.1016/j.bbrc.2020.03.051

    Article  CAS  PubMed  Google Scholar 

  10. Dafinca R, Scaber J, Ababneh N, Lalic T, Weir G, Christian H, Vowles J, Douglas AG, Fletcher-Jones A, Browne C et al (2016) C9orf72 hexanucleotide expansions are associated with altered endoplasmic reticulum calcium homeostasis and stress granule formation in induced pluripotent stem cell-derived neurons from patients with amyotrophic lateral sclerosis and frontotemporal dementia. Stem Cells 34:2063–2078. https://doi.org/10.1002/stem.2388

    Article  CAS  PubMed  Google Scholar 

  11. Deng HX, Zhai H, Bigio EH, Yan J, Fecto F, Ajroud K, Mishra M, Ajroud-Driss S, Heller S, Sufit R et al (2010) FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Ann Neurol 67:739–748. https://doi.org/10.1002/ana.22051

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ederle H, Dormann D (2017) TDP-43 and FUS en route from the nucleus to the cytoplasm. FEBS Lett 591:1489–1507. https://doi.org/10.1002/1873-3468.12646

    Article  CAS  PubMed  Google Scholar 

  13. Farrawell NE, McAlary L, Lum JS, Chisholm CG, Warraich ST, Blair IP, Vine KL, Saunders DN, Yerbury JJ (2020) Ubiquitin homeostasis is disrupted in TDP-43 and FUS cell models of ALS. iScience 23:101700. https://doi.org/10.1016/j.isci.2020.101700

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Forsberg K, Graffmo K, Pakkenberg B, Weber M, Nielsen M, Marklund S, Brannstrom T, Andersen PM (2019) Misfolded SOD1 inclusions in patients with mutations in C9orf72 and other ALS/FTD-associated genes. J Neurol Neurosurg Psychiatry 90:861–869. https://doi.org/10.1136/jnnp-2018-319386

    Article  PubMed  Google Scholar 

  15. Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, Hultdin M, Jacobsson J, Rosquist R, Marklund SL, Brannstrom T (2010) Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS ONE 5:e11552. https://doi.org/10.1371/journal.pone.0011552

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Furukawa Y, Kaneko K, Yamanaka K, O’Halloran TV, Nukina N (2008) Complete loss of post-translational modifications triggers fibrillar aggregation of SOD1 in the familial form of amyotrophic lateral sclerosis. J Biol Chem 283:24167–24176. https://doi.org/10.1074/jbc.M802083200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Gal J, Strom AL, Kilty R, Zhang F, Zhu H (2007) p62 accumulates and enhances aggregate formation in model systems of familial amyotrophic lateral sclerosis. J Biol Chem 282:11068–11077. https://doi.org/10.1074/jbc.M608787200

    Article  CAS  PubMed  Google Scholar 

  18. Gal J, Strom AL, Kwinter DM, Kilty R, Zhang J, Shi P, Fu W, Wooten MW, Zhu H (2009) Sequestosome 1/p62 links familial ALS mutant SOD1 to LC3 via an ubiquitin-independent mechanism. J Neurochem 111:1062–1073. https://doi.org/10.1111/j.1471-4159.2009.06388.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Guareschi S, Cova E, Cereda C, Ceroni M, Donetti E, Bosco DA, Trotti D, Pasinelli P (2012) An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1. Proc Natl Acad Sci U S A 109:5074–5079. https://doi.org/10.1073/pnas.1115402109

    Article  PubMed  PubMed Central  Google Scholar 

  20. Hadano S, Mitsui S, Pan L, Otomo A, Kubo M, Sato K, Ono S, Onodera W, Abe K, Chen X et al (2016) Functional links between SQSTM1 and ALS2 in the pathogenesis of ALS: cumulative impact on the protection against mutant SOD1-mediated motor dysfunction in mice. Hum Mol Genet 25:3321–3340. https://doi.org/10.1093/hmg/ddw180

    Article  CAS  PubMed  Google Scholar 

  21. Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle F, Morita M et al (2008) Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol 64:60–70. https://doi.org/10.1002/ana.21425

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Huang C, Yan S, Zhang Z (2020) Maintaining the balance of TDP-43, mitochondria, and autophagy: a promising therapeutic strategy for neurodegenerative diseases. Transl Neurodegener 9:40. https://doi.org/10.1186/s40035-020-00219-w

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Jeon GS, Shim YM, Lee DY, Kim JS, Kang M, Ahn SH, Shin JY, Geum D, Hong YH, Sung JJ (2019) Pathological modification of TDP-43 in amyotrophic lateral sclerosis with SOD1 mutations. Mol Neurobiol 56:2007–2021. https://doi.org/10.1007/s12035-018-1218-2

    Article  CAS  PubMed  Google Scholar 

  24. Liu WJ, Ye L, Huang WF, Guo LJ, Xu ZG, Wu HL, Yang C, Liu HF (2016) p62 links the autophagy pathway and the ubiqutin-proteasome system upon ubiquitinated protein degradation. Cell Mol Biol Lett 21:29. https://doi.org/10.1186/s11658-016-0031-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, Kwong LK, Forman MS, Ravits J, Stewart H et al (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 61:427–434. https://doi.org/10.1002/ana.21147

    Article  CAS  PubMed  Google Scholar 

  26. Mandrioli J, D’Amico R, Zucchi E, Gessani A, Fini N, Fasano A, Caponnetto C, Chio A, Dalla Bella E, Lunetta C et al (2018) Rapamycin treatment for amyotrophic lateral sclerosis: protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). Medicine (Baltimore) 97:e11119. https://doi.org/10.1097/MD.0000000000011119

    Article  CAS  Google Scholar 

  27. Marrone L, Drexler HCA, Wang J, Tripathi P, Distler T, Heisterkamp P, Anderson EN, Kour S, Moraiti A, Maharana S et al (2019) FUS pathology in ALS is linked to alterations in multiple ALS-associated proteins and rescued by drugs stimulating autophagy. Acta Neuropathol 138:67–84. https://doi.org/10.1007/s00401-019-01998-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. McCann EP, Williams KL, Fifita JA, Tarr IS, O’Connor J, Rowe DB, Nicholson GA, Blair IP (2017) The genotype-phenotype landscape of familial amyotrophic lateral sclerosis in Australia. Clin Genet. https://doi.org/10.1111/cge.12973

    Article  PubMed  Google Scholar 

  29. Medinas DB, Rozas P, Martinez Traub F, Woehlbier U, Brown RH, Bosco DA, Hetz C (2018) Endoplasmic reticulum stress leads to accumulation of wild-type SOD1 aggregates associated with sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 115:8209–8214. https://doi.org/10.1073/pnas.1801109115

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Medinas DB, Valenzuela V, Hetz C (2017) Proteostasis disturbance in amyotrophic lateral sclerosis. Hum Mol Genet 26:R91–R104. https://doi.org/10.1093/hmg/ddx274

    Article  CAS  PubMed  Google Scholar 

  31. Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, Genge A, Glass J, Ladha S, Ludolph AL et al (2020) Phase 1–2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 383:109–119. https://doi.org/10.1056/NEJMoa2003715

    Article  CAS  PubMed  Google Scholar 

  32. Mitsui S, Otomo A, Nozaki M, Ono S, Sato K, Shirakawa R, Adachi H, Aoki M, Sobue G, Shang HF et al (2018) Systemic overexpression of SQSTM1/p62 accelerates disease onset in a SOD1(H46R)-expressing ALS mouse model. Mol Brain 11:30. https://doi.org/10.1186/s13041-018-0373-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Mizuno Y, Amari M, Takatama M, Aizawa H, Mihara B, Okamoto K (2006) Immunoreactivities of p62, an ubiqutin-binding protein, in the spinal anterior horn cells of patients with amyotrophic lateral sclerosis. J Neurol Sci 249:13–18. https://doi.org/10.1016/j.jns.2006.05.060

    Article  CAS  PubMed  Google Scholar 

  34. Nonaka T, Suzuki G, Tanaka Y, Kametani F, Hirai S, Okado H, Miyashita T, Saitoe M, Akiyama H, Masai H et al (2016) Phosphorylation of TAR DNA-binding protein of 43 kDa (TDP-43) by truncated casein kinase 1delta triggers mislocalization and accumulation of TDP-43. J Biol Chem 291:5473–5483. https://doi.org/10.1074/jbc.M115.695379

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Pankiv S, Lamark T, Bruun JA, Overvatn A, Bjorkoy G, Johansen T (2010) Nucleocytoplasmic shuttling of p62/SQSTM1 and its role in recruitment of nuclear polyubiquitinated proteins to promyelocytic leukemia bodies. J Biol Chem 285:5941–5953. https://doi.org/10.1074/jbc.M109.039925

    Article  CAS  PubMed  Google Scholar 

  36. Pokrishevsky E, Grad LI, Yousefi M, Wang J, Mackenzie IR, Cashman NR (2012) Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PLoS ONE 7:e35050. https://doi.org/10.1371/journal.pone.0035050

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L et al (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72:257–268. https://doi.org/10.1016/j.neuron.2011.09.010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Roberts BR, Lim NK, McAllum EJ, Donnelly PS, Hare DJ, Doble PA, Turner BJ, Price KA, Lim SC, Paterson BM et al (2014) Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 34:8021–8031. https://doi.org/10.1523/JNEUROSCI.4196-13.2014

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Robertson J, Sanelli T, Xiao S, Yang W, Horne P, Hammond R, Pioro EP, Strong MJ (2007) Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS. Neurosci Lett 420:128–132. https://doi.org/10.1016/j.neulet.2007.03.066

    Article  CAS  PubMed  Google Scholar 

  40. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, Oregan JP, Deng HX et al (1993) Mutations in Cu/Zn Superoxide-dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59–62. https://doi.org/10.1038/362059a0

    Article  CAS  PubMed  Google Scholar 

  41. Soo KY, Halloran M, Sundaramoorthy V, Parakh S, Toth RP, Southam KA, McLean CA, Lock P, King A, Farg MA et al (2015) Rab1-dependent ER-Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS. Acta Neuropathol 130:679–697. https://doi.org/10.1007/s00401-015-1468-2

    Article  CAS  PubMed  Google Scholar 

  42. Soto C, Pritzkow S (2018) Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci 21:1332–1340. https://doi.org/10.1038/s41593-018-0235-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Spires-Jones TL, Attems J, Thal DR (2017) Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol 134:187–205. https://doi.org/10.1007/s00401-017-1709-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Suk TR, Rousseaux MWC (2020) The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener 15:45. https://doi.org/10.1186/s13024-020-00397-1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Sundaramoorthy V, Walker AK, Yerbury J, Soo KY, Farg MA, Hoang V, Zeineddine R, Spencer D, Atkin JD (2013) Extracellular wildtype and mutant SOD1 induces ER-Golgi pathology characteristic of amyotrophic lateral sclerosis in neuronal cells. Cell Mol Life Sci 70:4181–4195. https://doi.org/10.1007/s00018-013-1385-2

    Article  CAS  PubMed  Google Scholar 

  46. Tanji K, Zhang HX, Mori F, Kakita A, Takahashi H, Wakabayashi K (2012) p62/sequestosome 1 binds to TDP-43 in brains with frontotemporal lobar degeneration with TDP-43 inclusions. J Neurosci Res 90:2034–2042. https://doi.org/10.1002/jnr.23081

    Article  CAS  PubMed  Google Scholar 

  47. Trist BG, Genoud S, Roudeau S, Rookyard A, Abdeen A, Cottam V, Hare DJ, White M, Altvater J, Fifita JA et al (2022) Altered SOD1 maturation and post-translational modification in amyotrophic lateral sclerosis spinal cord. Brain. https://doi.org/10.1093/brain/awac165

    Article  PubMed  Google Scholar 

  48. Trist BG, Hilton JB, Hare DJ, Crouch PJ, Double KL (2020) Superoxide dismutase 1 in health and disease: how a frontline antioxidant becomes neurotoxic. Angew Chem Int Ed Engl. https://doi.org/10.1002/anie.202000451

    Article  PubMed  PubMed Central  Google Scholar 

  49. Williams JR, Trias E, Beilby PR, Lopez NI, Labut EM, Bradford CS, Roberts BR, McAllum EJ, Crouch PJ, Rhoads TW et al (2016) Copper delivery to the CNS by CuATSM effectively treats motor neuron disease in SOD(G93A) mice co-expressing the Copper-Chaperone-for-SOD. Neurobiol Dis 89:1–9. https://doi.org/10.1016/j.nbd.2016.01.020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Zeineddine R, Farrawell NE, Lambert-Smith IA, Yerbury JJ (2017) Addition of exogenous SOD1 aggregates causes TDP-43 mislocalisation and aggregation. Cell Stress Chaperones 22:893–902. https://doi.org/10.1007/s12192-017-0804-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Tissues were received from the University of Maryland Brain and Tissue Bank, a biorepository of the NIH NeuroBioBank, as well as from the Sydney Brain Bank, which is supported by Neuroscience Research Australia and the University of New South Wales, and finally from The London Neurodegenerative Diseases Brain Bank, which receives funding from the Medical Research Council and the Brains for Dementia Research programme, jointly funded by Alzheimer’s Research UK and Alzheimer’s Society. The authors thank Heath McCann of the Sydney Brain Bank for her assistance in embedding fixed tissues obtained from other brain banks. The authors acknowledge the facilities as well as the scientific and technical assistance of the Australian Microscopy and Microanalysis Research Facility (http://ammrf.org.au) node at the University of Sydney, in particular Dr. Michael Kuligowski and Dr. Pamela Young.

Funding

B.G.T. and K.L.D. are funded by MND Research Australia (Innovator Grant Scheme). J.A.F is funded by MND Research Australia (Bill Gole Fellowship). C.V. is funded by Motor Neurone Disease Association UK. This study was supported by ForeFront, a large collaborative research group dedicated to the study of neurodegenerative diseases and funded by the National Health and Medical Research Council of Australia Program Grant (1132524), Dementia Research Team Grant (1095127) and CogSleep Centre of Research Excellence (1152945).

Author information

Authors and Affiliations

  1. Brain and Mind Centre and School of Medical Sciences (Neuroscience), Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, 2006, Australia

    Benjamin G. Trist & Kay L. Double

  2. Centre for Motor Neuron Disease Research, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia

    Jennifer A. Fifita, Alison Hogan, Natalie Grima & Ian P. Blair

  3. Maurice Wohl Clinical Neuroscience Institute and the Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Camberwell, London, SE5 9RT, UK

    Bradley Smith, Caroline Vance & Christopher Shaw

  4. London Neurodegenerative Diseases Brain Bank, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, SE5 8AF, UK

    Claire Troakes & Safa Al-Sarraj

Authors
  1. Benjamin G. Trist
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer A. Fifita
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alison Hogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Natalie Grima
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bradley Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Claire Troakes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Caroline Vance
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christopher Shaw
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Safa Al-Sarraj
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ian P. Blair
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kay L. Double
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

BGT and KD designed the study, obtained project funding, acquired human research ethics, and sourced human post-mortem tissues. BS, CT, CV, CS, SA provided patient details for human post-mortem tissues. JAF, AH, NG, IPB performed genotyping experiments. BGT processed human tissues, performed immunohistochemical experiments, analysed data and wrote the manuscript. BGT and KLD revised the manuscript and KLD supervised the study. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Benjamin G. Trist or Kay L. Double.

Ethics declarations

Ethics approval and consent to participate

Ethics approval was obtained from the University of Sydney Human Research Ethics Committee (approval number 2019/309).

Consent for publication

Not applicable.

Competing interests

All authors report no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

Demographic and clinical information for human post-mortem tissue cases. Table S2. Demographic statistics for diagnostic groups. Table S3. Primary antibody details and applications. Table S4. Number of spinal cord motor neurons examined across all cases of each diagnostic group for quantification of each pathology of interest. Fig. S1. No primary controls and spectral validation of fluorescent microscopy workflow.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Trist, B.G., Fifita, J.A., Hogan, A. et al. Co-deposition of SOD1, TDP-43 and p62 proteinopathies in ALS: evidence for multifaceted pathways underlying neurodegeneration. acta neuropathol commun 10, 122 (2022). https://doi.org/10.1186/s40478-022-01421-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40478-022-01421-9

Keywords

  • Superoxide dismutase-1
  • TAR DNA-binding protein 43
  • p62/SQSTM1
  • Proteinopathy
  • Amyotrophic lateral sclerosis

Acta Neuropathologica Communications

ISSN: 2051-5960

Contact us